A Case of Hand-Foot Skin Reaction-like Eruption Associated with Pembrolizumab

Main Article Content

Jade Young
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Anna Eversman
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Dina Poplausky
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Yamato Suemitsu
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

George Niedt
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Matthew Galsky
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Joseph Sparano
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Nicholas Gulati
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Keywords

hand food skin reaction, HFSR, cutaneous immune-related adverse event, cirae, immunotherapy, immune-checkpoint inhibitor, ICI, pembrolizumab, oncodermatology

References

1. Said JT, Singer S, Iannattone L, Sauder M, LeBoeuf NR. Outcomes of Acitretin Treatment for Refractory Multikinase Inhibitor–Induced Hand-Foot Skin Reaction. JAMA Dermatol. 2022;158(7):824-826. doi:10.1001/jamadermatol.2022.1425

2. Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(5):579-597. doi:10.1016/j.jaccao.2022.09.004

3. Yang C, Lin W, Chuang C, et al. Hand‐foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. British Journal of Dermatology. 2008;158(3):592-596. doi:10.1111/j.1365-2133.2007.08357.x

4. Chanprapaph K, Rutnin S, Vachiramon V. Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol. 2016;17(4):387-402. doi:10.1007/s40257-016-0197-1

5. Anderson RT, Keating KN, Doll HA, Camacho F. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. Oncologist. 2015;20(7):831-838. doi:10.1634/theoncologist.2014-0219

Article Sidebar

PDF
Published
Mar 18, 2024
DOI https://doi.org/10.25251/skin.8.2.21

Article Details

How to Cite
[1]
Young, J., Eversman, A., Poplausky, D., Suemitsu, Y., Niedt, G. , Galsky, M., Sparano, J. and Gulati, N. 2024. A Case of Hand-Foot Skin Reaction-like Eruption Associated with Pembrolizumab . SKIN The Journal of Cutaneous Medicine. 8, 2 (Mar. 2024), 1464–1467. DOI:https://doi.org/10.25251/skin.8.2.21.
Issue
Vol. 8 No. 2 (2024): March 2024 Issue
Section
Short Communications
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.